Dr. Reddy's Laboratories is gunning for Pfizer’s extended-release overactive bladder treatment Toviaz, introducing a therapeutic generic equivalent that could threaten more than $200 million in revenues.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,